ALLERGAN FDA Approval NDA 021365

NDA 021365

ALLERGAN

FDA Drug Application

Application #021365

Documents

Letter2002-11-27
Letter2003-12-22
Letter2003-12-22
Letter2005-01-13
Letter2004-05-26
Letter2005-02-23
Letter2008-09-19
Letter2008-10-21
Letter2009-03-24
Letter2009-02-03
Letter2011-05-16
Letter2011-03-16
Letter2014-11-03
Label2003-12-22
Label2003-12-22
Label2009-03-25
Label2011-05-16
Label2011-03-11
Review2007-07-06
Review2007-07-06
Other Important Information from FDA2005-07-29
Letter2009-03-24
Letter2012-12-05
Letter2014-07-10
Label2002-11-27
Label2008-09-19
Label2009-03-25
Label2009-02-04
Label2012-12-03
Label2014-11-04
Label2014-07-21
Review2004-06-29
Label2017-01-06
Medication Guide2017-01-11
Letter2017-01-11
Label2019-01-14
Letter2019-01-18
Letter2020-09-01
Label2020-09-04
Letter2021-09-22
Label2021-09-24
Medication Guide2021-09-24

Application Sponsors

NDA 021365ALLERGAN

Marketing Status

Discontinued001

Application Products

001SOLUTION;ORALEQ 5MG BASE/5ML1LEXAPROESCITALOPRAM OXALATE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2002-11-27STANDARD
EFFICACY; EfficacySUPPL4AP2003-12-18STANDARD
S; SupplementSUPPL5AP2004-04-08STANDARD
LABELING; LabelingSUPPL7AP2005-01-11STANDARD
LABELING; LabelingSUPPL8AP2004-05-20STANDARD
LABELING; LabelingSUPPL12AP2005-02-18STANDARD
LABELING; LabelingSUPPL16AP2007-08-02STANDARD
LABELING; LabelingSUPPL18AP2008-09-18STANDARD
LABELING; LabelingSUPPL19AP2008-10-11STANDARD
EFFICACY; EfficacySUPPL21AP2009-03-19UNKNOWN
EFFICACY; EfficacySUPPL22AP2009-03-19UNKNOWN
LABELING; LabelingSUPPL23AP2009-01-30STANDARD
LABELING; LabelingSUPPL24AP2011-05-12STANDARD
LABELING; LabelingSUPPL25AP2011-03-11UNKNOWN
LABELING; LabelingSUPPL30AP2012-12-03STANDARD
LABELING; LabelingSUPPL32AP2014-10-31STANDARD
LABELING; LabelingSUPPL33AP2014-07-08901 REQUIRED
LABELING; LabelingSUPPL35AP2017-01-04901 REQUIRED
LABELING; LabelingSUPPL36AP2019-01-11STANDARD
LABELING; LabelingSUPPL37AP2020-08-28STANDARD
LABELING; LabelingSUPPL38AP2021-09-20901 REQUIRED

Submissions Property Types

SUPPL5Null0
SUPPL21Null4
SUPPL22Null4
SUPPL24Null7
SUPPL25Null6
SUPPL30Null15
SUPPL32Null7
SUPPL33Null15
SUPPL35Null7
SUPPL36Null15
SUPPL37Null6
SUPPL38Null6

TE Codes

001PrescriptionAA

CDER Filings

ALLERGAN
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21365
            [companyName] => ALLERGAN
            [docInserts] => ["Medication Guide","http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021323s047lbl.pdf#page=24"]
            [products] => [{"drugName":"LEXAPRO","activeIngredients":"ESCITALOPRAM OXALATE","strength":"EQ 5MG BASE\/5ML","dosageForm":"SOLUTION;ORAL","marketingStatus":"Discontinued","te":"None","rld":"Yes","rs":"No"}]
            [labels] => [{"actionDate":"01\/11\/2019","submission":"SUPPL-36","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/021323s051,021365s036lbl.pdf\"}]","notes":""},{"actionDate":"01\/04\/2017","submission":"SUPPL-35","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/021365s035lbl.pdf\"}]","notes":""},{"actionDate":"10\/31\/2014","submission":"SUPPL-32","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/021323s044,021365s032lbl.pdf\"}]","notes":""},{"actionDate":"07\/08\/2014","submission":"SUPPL-33","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/021323Orig1s045,021365Orig1s033lbl.pdf\"}]","notes":""},{"actionDate":"12\/03\/2012","submission":"SUPPL-30","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2012\\\/021365s030lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2011","submission":"SUPPL-24","supplementCategories":"Labeling-Medication Guide","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2011\\\/021323s033,021365s024lbl.pdf\"}]","notes":""},{"actionDate":"03\/11\/2011","submission":"SUPPL-25","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2011\\\/021323s035,021365s025lbl.pdf\"}]","notes":""},{"actionDate":"03\/19\/2009","submission":"SUPPL-22","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2009\\\/021323s030s031,021365s021s022lbl.pdf\"}]","notes":""},{"actionDate":"03\/19\/2009","submission":"SUPPL-21","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2009\\\/021323s030s031,021365s021s022lbl.pdf\"}]","notes":""},{"actionDate":"01\/30\/2009","submission":"SUPPL-23","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2009\\\/021323s032,021365s023lbl.pdf\"}]","notes":""},{"actionDate":"09\/18\/2008","submission":"SUPPL-18","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2008\\\/021323s28s29,021365s18s19lbl.pdf\"}]","notes":""},{"actionDate":"12\/18\/2003","submission":"SUPPL-4","supplementCategories":"Efficacy-New Indication","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2003\\\/21323se1-003,se8-007,21365se8-001,se1-004_lexapro_lbl.pdf\"}]","notes":""},{"actionDate":"12\/18\/2003","submission":"SUPPL-1","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2003\\\/21323se1-003,se8-007,21365se8-001,se1-004_lexapro_lbl.pdf\"}]","notes":""},{"actionDate":"11\/27\/2002","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21365_Lexapro_lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"LEXAPRO","submission":"ESCITALOPRAM OXALATE","actionType":"EQ 5MG BASE\/5ML","submissionClassification":"SOLUTION;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2019-01-11
        )

)
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.